Persistent PSA salvage radiotherapy cohort (N = 69) | CFR group 66 Gy in 33 fractions (N = 36) | HFR group 52.5 Gy in 20 fractions (N = 33) | p-value | |
---|---|---|---|---|
Age, yr, median (IQR) | 63 (59–68) | 63 (55–68) | 64 (59–68) | 0.90 |
Follow-up post RT, Months, median (IQR) | 59 (49–74) | 59 (50–73) | 64 (46–76) | 0.98 |
First post- prostatectomy PSA, ng/mL Median (IQR) | 0.33 (0.16–1.57) | 0.3 (0.14–1.5) | 0.36 (0.2–2.4) | 0.16 |
PreRT PSA, ng/mL, median (IQR) | 0.56 (0.30–1.83) | 0.55 (0.29–1.71) | 0.60 (0.33–2.39) | 0.25 |
PreRT PSA, ng/mL, range | 0.1–30.0 | 0.12–12.5 | 0.10–30.0 | |
ADT during RT, N (%) | 47 (68) | 29 (81) | 18 (55) | 0.02 |
Bicalutamide 150 mg, N (%) | 23 (49) | 16 (55) | 7 (39) | |
LHRH agonist, N (%) | 24 (51) | 13 (45) | 11 (61) | |
Duration of ADT, Months, median (IQR) | 24 (6–27) | 24 (6–30) | 24 (21–27) | 0.04 |
Final pathology Grade Group (GG), N (%) | 0.021 | |||
GG 1 | 3 (4) | 3 (8) | / | |
GG 2 | 27 (39) | 11 (30) | 166 (48) | |
GG 3 | 21 (30) | 13 (36) | 8 (24) | |
GG 4 | 8 (11) | 6 (16) | 2 (6) | |
GG 5 | 10 (16) | 3 (10) | 7 (22) | |
pT stage, N (%) | 0.08 | |||
T1–T2a | 7 (10) | 6 (16) | 1 (3) | |
T2b–T2c | 22 (32) | 13 (36) | 9 (27) | |
T3–T4 | 40 (58) | 17 (19) | 23 (70) | |
SVI, N (%) | 33 (48) | 12 (33) | 11 (33) | 1.0 |
Positive SM, N (%) | 28 (41) | 14 (39) | 14 (42) | 0.77 |
ECE, N (%) | 32 (46) | 13 (36) | 19 (58) | 0.08 |